BICX Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 13.1%. BioCorRx, Inc.'s return on equity of -- beat Encompass Health Corp.'s return on equity of 24.74%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 158.07%. On the other hand Encompass Health Corp. has an analysts' consensus of $142.73 which suggests that it could grow by 27.37%. Given that BioCorRx, Inc. has higher upside potential than Encompass Health Corp., analysts believe BioCorRx, Inc. is more attractive than Encompass Health Corp..

BioCorRx, Inc. has a beta of 0.414, which suggesting that the stock is 58.601% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.06%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.64% to investors and pays a quarterly dividend of $0.19 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 13% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. BioCorRx, Inc.'s net income of -$808.5K is lower than Encompass Health Corp.'s net income of $202.3M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Encompass Health Corp.'s PE ratio is 20.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 5.19x versus 1.93x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Elite Health Systems, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of --. BioCorRx, Inc.'s return on equity of -- beat Elite Health Systems, Inc.'s return on equity of -72.99%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 158.07%. On the other hand Elite Health Systems, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioCorRx, Inc. has higher upside potential than Elite Health Systems, Inc., analysts believe BioCorRx, Inc. is more attractive than Elite Health Systems, Inc..

BioCorRx, Inc. has a beta of 0.414, which suggesting that the stock is 58.601% less volatile than S&P 500. In comparison Elite Health Systems, Inc. has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.5%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elite Health Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Elite Health Systems, Inc. pays out -- of its earnings as a dividend.

BioCorRx, Inc. quarterly revenues are $635.2K, which are larger than Elite Health Systems, Inc. quarterly revenues of --. BioCorRx, Inc.'s net income of -$808.5K is higher than Elite Health Systems, Inc.'s net income of -$1.2M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Elite Health Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 5.19x versus 7.08x for Elite Health Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 14.55%. BioCorRx, Inc.'s return on equity of -- beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 158.07%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 7.58%. Given that BioCorRx, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe BioCorRx, Inc. is more attractive than Pediatrix Medical Group, Inc..

BioCorRx, Inc. has a beta of 0.414, which suggesting that the stock is 58.601% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.082%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. BioCorRx, Inc.'s net income of -$808.5K is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 11.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 5.19x versus 0.94x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of -127.28% compared to BioCorRx, Inc.'s net margin of 9.98%. BioCorRx, Inc.'s return on equity of -- beat U.S. Physical Therapy, Inc.'s return on equity of 8.6%.

BioCorRx, Inc. has a consensus price target of --, signalling upside risk potential of 158.07%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 19.51%. Given that BioCorRx, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe BioCorRx, Inc. is more attractive than U.S. Physical Therapy, Inc..

BioCorRx, Inc. has a beta of 0.414, which suggesting that the stock is 58.601% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.297, suggesting its more volatile than the S&P 500 by 29.702%.

BioCorRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.04% to investors and pays a quarterly dividend of $0.45 per share. BioCorRx, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 95.62% of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCorRx, Inc. quarterly revenues are $635.2K, which are smaller than U.S. Physical Therapy, Inc. quarterly revenues of $197.1M. BioCorRx, Inc.'s net income of -$808.5K is lower than U.S. Physical Therapy, Inc.'s net income of $19.7M. Notably, BioCorRx, Inc.'s price-to-earnings ratio is -- while U.S. Physical Therapy, Inc.'s PE ratio is 37.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCorRx, Inc. is 5.19x versus 1.76x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.